Featured

Hello, India!

This featured post is about ChartAlert, a Real-Time-Enabled and End-of-Day Technical Analysis Advisory, Charting and Scanning Desktop Software

1–2 minutes

ChartAlert® is a Microsoft® Windows® compatible Real-Time-Enabled and End-of-Day Technical Analysis Advisory, Charting and Scanning Desktop Software that complements your trading and investing needs.

ChartAlert features three seamless modules.

1. The Charting module includes Charting and Masks.

2. The Reporting module includes Basic Advisory Content and Market Reports.

3. The Scanning module includes Basic Scanner, Advanced Scanner, RS Matrix & Trend Matrix, Trading Systems Builder and the Backtester.

Continue reading “Hello, India!”

India’s 20 years of GDP misestimation: New evidence (PIIE)

The authors — Abhishek Anand (Madras Institute of Development Studies), Josh Felman (JH Consulting) and Arvind Subramanian (Peterson Institute for International Economics) — imply India’s post-2011 GDP growth was structurally overstated by ~1.5–2.0% due to deflator and informal-sector mismeasurement, forcing investors to haircut cyclical exposures, reassess consumption-driven bets, and price in policy recalibration risks.

1–2 minutes

Based on the paper “India’s 20 years of GDP misestimation: New evidence” by authors Abhishek Anand (Madras Institute of Development Studies), Josh Felman (JH Consulting) and Arvind Subramanian (Peterson Institute for International Economics).

 The authors — Abhishek Anand (Madras Institute of Development Studies), Josh Felman (JH Consulting) and Arvind Subramanian (Peterson Institute for International Economics) — imply India’s post-2011 GDP growth was structurally overstated by ~1.5–2.0% due to deflator and informal-sector mismeasurement, forcing investors to haircut cyclical exposures, reassess consumption-driven bets, and price in policy recalibration risks.

Continue reading “India’s 20 years of GDP misestimation: New evidence (PIIE)”

ZYDUSLIFE – Q3 FY26 Earnings Call – 10-Feb-26

ZYDUSLIFE’s topline: 12–15% CAGR driven by US specialty, India chronic portfolio, and International Markets; Bottomline: 8–10% EPS growth contingent on margin stability and R&D efficiency; Margins: 23–25% EBITDA range, with upside from biosimilar scaling and downside from acquisition dilution.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

  • Key Variables: Mirabegron settlement; CDMO revenue ramp-up in H2 FY27; biosimilar launches on schedule.
  • Outcome: US revenue grows 8–10% YoY, driven by specialty and generics volume. EBITDA margins stabilize at 23–25%. India and International Markets sustain 15–20% growth. Net debt reduces to ₹2,500Cr by FY28 as cash flows improve. GLP-1 captures 10–15% market share in India.
Continue reading “ZYDUSLIFE – Q3 FY26 Earnings Call – 10-Feb-26”

DIVISLAB – Q3 FY26 Earnings Call – 11-Feb-26

DIVISLAB’s growth relies on CS (57% mix), with generics resilient but pressured by pricing. Bottomline depends on CS commercialization (CY27) and cost pass-through, while margins face labor/raw material volatility, partly offset by backward integration and automation over 2–3 years.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) 2/3 CS projects commercialize in Q3–Q4 CY27; (2) Generic pricing stabilizes (China’s rebate removal lifts API prices by 3–5%). Outcome: Revenue 8–10% CAGR, EBITDA margins expand 50 bps (CS mix shift), and gross asset turnover improves to 1.4x by FY28. EPS grows 8–12% annually.

Continue reading “DIVISLAB – Q3 FY26 Earnings Call – 11-Feb-26”

INDHOTEL – Q3 FY26 Earnings Call – 12-Feb-26

INDHOTEL: Findings imply sustained double-digit topline growth (12%–14%) with EBITDA margins at 39%–40% and PAT expansion (15%–18%), contingent on RevPAR resilience, acquisition execution, and capex discipline—structural diversification and asset-light scaling remain key differentiators.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

  • RevPAR Resilience: 8.5%–10% domestic RevPAR + 12%–14% consolidated revenue growth (60+ openings, F&B/spa upside). Taj Bandstand on track for ₹1,000 crore stabilization.
  • Acquisition Synergies: Ginger reaches 250+ hotels; Atmantan/Brij contribute ₹250–300 crore. EBITDA margin sustains at 39%–40%.
  • Implication: Double-digit PAT growth (15%–18%), management fee income grows high-teens, and capital-light model drives ROIC expansion.
Continue reading “INDHOTEL – Q3 FY26 Earnings Call – 12-Feb-26”

VBL (Varun Beverages) – Q3 FY26 Earnings Call – 3-Feb-26

VBL’s topline hinges on weather normalization and Twizza execution, with 10–15% growth probable; bottomline leverages operating scale and cost absorption, targeting 12–20% EPS upside; margins face cyclical realization pressure but structural backward integration supports 23–26% India EBITDA and 17–20% ex-India EBITDA by 2027.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

  • Key Variables: Normal weather, Twizza synergies on track, snacks scale to ₹500cr.
  • Outcome: Volumes grow 10–12%; realization improves 2–3% on mix. India EBITDA margins sustain at 24–25%; ex-India margins expand to 17–18%. Free cash flow funds Twizza and brewery; dividend hike likely. Topline: +10–12%; Bottomline: +12–15%.
Continue reading “VBL (Varun Beverages) – Q3 FY26 Earnings Call – 3-Feb-26”

MOTHERSON – Q3 FY26 Earnings Call – 10-Feb-26

Motherson FY27 outlook: Revenue growth (8–15%) depends on Greenfield execution and European OEM strength; consumer electronics/aerospace scalability is pivotal. EBITDA margins may swing 50–200 bps from commodity/FX, but efficiencies and ROCE discipline cushion downside. Non-auto expansion (40%+ ROCE) offsets auto cyclicality if execution succeeds.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) European OEMs stabilize market share; (2) Greenfields contribute 70% of targeted FY27 revenue; (3) consumer electronics/aerospace scale to 20M units/year by FY28.
Outcome: Revenue grows 10–12% YoY in FY27; EBITDA margins expand 50–100 bps on operational efficiencies and FX tailwinds. Leverage remains 1.0–1.2x; ROCE in new ventures hits 35–40%. Implication: Sustainable topline growth; margin expansion offsets cyclical pressures.

Continue reading “MOTHERSON – Q3 FY26 Earnings Call – 10-Feb-26”

GRASIM – Q3 FY26 Earnings Call – 11-Feb-26

Topline likely to sustain 20%+ YoY growth led by paints/B2B, but bottomline hinges on B2B breakeven timing and margin expansion in chemicals/renewables; structural premiumization in paints offsets cyclical chemical pressures, while CAPEX completion unlocks free cash flow from FY27.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

  • Key Variables: Paints price hike sticks (elasticity ~0.8x), B2B hits FY27 breakeven, chemicals EBITDA stabilizes (+2% YoY).
  • Outcome: Revenue grows 20–22% YoY; EBITDA margins expand to 15–16% on operational leverage. Paints EBITDA breakeven in FY28; B2B contributes 10% of consolidated EBITDA by FY29.
Continue reading “GRASIM – Q3 FY26 Earnings Call – 11-Feb-26”

HINDALCO – Q3 FY26 Earnings Call – 12-Feb-26

Hindalco’s topline growth hinges on Bay Minette/Aditya Refinery execution and LME trends; bottomline volatility driven by Oswego insurance timing and hedge roll-offs; margins resilient in India (structural cost advantage) but Novelis recovery lags until FY28.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

  • Key Variables: Oswego restarts Q1 FY27; Bay Minette Phase 1 on budget/schedule; LME prices flat; Chakla mine operational by 1H FY27.
  • Outcome: Novelis EBITDA/ton recovers to $550–$600 by FY28; India upstream margins sustain at 43–45%; net debt/EBITDA stabilizes at 1.8–2.0x. $300M cost savings target met, supporting $150M+ FCF post-FY27.
Continue reading “HINDALCO – Q3 FY26 Earnings Call – 12-Feb-26”

APOLLOHOSP – Q3 FY26 Earnings Call – 11-Feb-26

Apollo Hospital’s topline likely grows 12–15% in FY’27 (existing hospitals + phased bed additions), but bottomline faces 100–150 bps margin compression from new hospitals; digital profitability and Keimed synergies are binary catalysts for re-rating or de-rating.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

  • Key variables: 50% of 750 beds operational by FY’27, digital cash EBITDA breakeven in Q1 FY’27, and 3% pricing power in CONGO-T.
  • Outcome: Revenue grows 12–14%, EBITDA margins flat YoY (new hospital losses offset by existing hospital expansion). Keimed synergies partially realized; pharmacy delivers 18% same-store growth. Implication: EPS grows 10–12%; FCF breakeven in FY’28.
Continue reading “APOLLOHOSP – Q3 FY26 Earnings Call – 11-Feb-26”

HINDUNILVR – Q3 FY26 Earnings Call – 12-Feb-26

Hindustan Unilever’s topline growth hinges on mass segment elasticity and quick commerce scalability, while EBITDA resilience depends on liquid premiumization and D2C margin delivery—model 6–8% revenue growth with 23% EBITDA as base, but skew risks to downside if rural demand or commodity pressures materialize.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) Urban consumption recovery (GST 2.0 tailwind, budget stimulus); (2) Benign commodity inflation (palm oil +5%, crude stable).
Outcome: Revenue grows 6–8% (UVG 4–5%) with broad-based category contributions. EBITDA holds at 23% as liquid premiumization and Horlicks relaunch offset QC investments. Signal: Quick commerce reaches 5% of sales with neutral margin impact; D2C brands deliver 20%+ growth.

Continue reading “HINDUNILVR – Q3 FY26 Earnings Call – 12-Feb-26”